Measuring Apex Biotechnology Corp.s (TSEC:1733) track record of past performance is an insightful exercise for investors. It enables us to reflect on whether the company has met or exceed expectations, which is a powerful signal for future performance. Below, I will assess 1733s recent performance announced on 31 December 2019 and compare these figures to its historical trend and industry movements. <\/p>\n
Check out our latest analysis for Apex Biotechnology <\/p>\n
1733s trailing twelve-month earnings (from 31 December 2019) of NT$114m has jumped 20% compared to the previous year. <\/p>\n
Furthermore, this one-year growth rate has exceeded its 5-year annual growth average of -28%, indicating the rate at which 1733 is growing has accelerated. Whats enabled this growth? Lets take a look at if it is merely due to industry tailwinds, or if Apex Biotechnology has experienced some company-specific growth. <\/p>\n
In terms of returns from investment, Apex Biotechnology has fallen short of achieving a 20% return on equity (ROE), recording 6.7% instead. Furthermore, its return on assets (ROA) of 4.3% is below the TW Medical Equipment industry of 6.2%, indicating Apex Biotechnologys are utilized less efficiently. And finally, its return on capital (ROC), which also accounts for Apex Biotechnologys debt level, has declined over the past 3 years from 12% to 9.3%. This correlates with an increase in debt holding, with debt-to-equity ratio rising from 21% to 29% over the past 5 years. <\/p>\n
Apex Biotechnologys track record can be a valuable insight into its earnings performance, but it certainly doesnt tell the whole story. Recent positive growth isnt always indicative of a continued optimistic outlook. There may be factors that are impacting the industry as a whole, thus the high industry growth rate over the same time period. You should continue to research Apex Biotechnology to get a better picture of the stock by looking at: <\/p>\n
NB: Figures in this article are calculated using data from the trailing twelve months from 31 December 2019. This may not be consistent with full year annual report figures.<\/p>\n
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com<\/a>. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.<\/p>\n We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.<\/p>\n <\/p>\n More: Measuring Apex Biotechnology Corp.s (TSEC:1733) track record of past performance is an insightful exercise for investors. It enables us to reflect on whether the company has met or exceed expectations, which is a powerful signal for future performance. Below, I will assess 1733s recent performance announced on 31 December 2019 and compare these figures to its historical trend and industry movements. Continue reading
\nDoes Apex Biotechnology Corp.s (TPE:1733) 20% Earnings Growth Make It An Outperformer? - Simply Wall St<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"